Biomedical Excellence For Safer Transfusion Colaborative
- Assets
- $902.3k
- Revenue
- $378.8k
- Investments
- $0.0
- Employees
- 0
- Location
- Los Angeles, CA
- Founding
- 11/2005
- Data as of
- 12/2022
- EIN
- 05-0602179
Organization Overview
Biomedical Excellence For Safer Transfusion Colaborative, operating under the name BEST Collaborative, is located in Los Angeles, CA. The organization was established in 2005. According to its NTEE Classification (U50) the organization is classified as: Biological & Life Sciences, under the broad grouping of Science & Technology and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. BEST Collaborative is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, BEST Collaborative generated $378.8k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 4 years, the organization has seen revenues fall by an average of (5.0%) each year. All expenses for the organization totaled $300.0k during the year ending 12/2022. As we would expect to see with falling revenues, expenses have declined by (5.7%) per year over the past 4 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
WE ARE A UNIQUE INTERNATIONAL COLLABORATIVE OF BLOOD PROVIDERS INDUSTRY AND ACADEMIC EXPERTS THAT WORK TOGETHER TO UNDERTAKE STUDIES PUBLISH GUIDANCE AND RECOMMEND PROCEDURES AIMING TO IMPROVE THE SAFETY QUALITY AND EFFECTIVENESS OF TRANSFUSION MEDICINE AND CELLULAR THERAPIES WORLDWIDE. WE USE OUR POOLED RESOURCES TO TAKE ON PROJECTS AND CHALLENGES THAT WOULD BE UNFEASIBLE TO ADDRESS OTHERWISE. WE CREATE INTERNATIONAL IMPACT IN TRANSFUSION AND CELLULAR THERAPIES FOR THE BENEFIT OF DONORS AND PATIENTS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
DIRK DE KORTE ET AL. THE BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION COLLABORATIVE. EVALUATION OF PLATELET CONCENTRATES PREPARED FROM WHOLE BLOOD DONATIONS WITH COLLECTION TIMES BETWEEN 12 AND 15 MIN: THE BEST COLLABORATIVE STUDY. VOX SANG 2022 MAY;1175:671-677. NANCY M DUNBAR ET AL. THE BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION BEST COLLABORATIVE. FACTORS ASSOCIATED WITH WRONG BLOOD IN TUBE ERRORS: AN INTERNATIONAL CASE SERIES - THE BEST COLLABORATIVE STUDY. TRANSFUSION. 2022 JAN;621:44-50. NISHAKA WILLIAM ET AL.ON BEHALF OF THE BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION BEST COLLABORATIVE. THE TIMING OF GAMMA IRRADIATION AND ITS EFFECT ON CELL-FREE AND MICROVESICLE-BOUND HEMOGLOBIN. THE BEST COLLABORATIVE STUDY. TRANSFUSION. 2022 APR;624:751-757. MEGHAN DELANEY ET AL ON BEHALF OF THE BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION BEST COLLABORATIVE. THE TIMING OF GAMMA IRRADIATION AND ITS EFFECT ON CELL-FREE AND MICROVESICLE-BOUND HEMOGLOBIN. THE BEST COLLABORATIVE STUDY. TRANSFUSION. 2022 APR;624:751-757. ANNA RAZATOS ET AL. BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION COLLABORATIVE. SURVEY OF BLOOD CENTRE READINESS REGARDING REMOVAL OF DEHP FROM BLOOD BAG SETS: THE BEST COLLABORATIVE STUDY. VOX SANG. 2022; JUN;1176:796-802. CYRIL JACQUOT ET AL.BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION BEST COLLABORATIVE. BLOOD DONOR ELIGIBILITY CRITERIA FOR MEDICAL CONDITIONS: A BEST COLLABORATIVE STUDY. VOX SANG. 2022 JUL;1177:929-936. JANSEN N. SEHEULT ET AL. THE BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION COLLABORATIVE. RATE OF D-ALLOIMMUNIZATION IN TRAUMA DOES NOT DEPEND ON THE NUMBER OF RHD-POSITIVE UNITS TRANSFUSED. THE BEST COLLABORATIVE STUDY. TRANSFUSION. 2022 AUG:6251:5185-5192. PATRICK TRÉPANIER ET AL. BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION COLLABORATIVE. MULTICENTER EVALUATION OF THE IL-3-PSTAT5 ASSAY TO ASSESS THE POTENCY OF CRYOPRESERVED STEM CELLS FROM CORD BLOOD UNITS: THE BEST COLLABORATIVE STUDY. TRANSFUSION. 2022 AUG:628: 1595-1604. FRANKEE QUEE ET AL. BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSION BEST COLLABORATIVE. WHOLE BLOOD DONOR RETURN RATES AFTER DEFERRAL FOR TATTOOING OR BODY PIERCING-SURVEY ACROSS BLOOD DONATION SERVICES: THE BEST COLLABORATIVE STUDY. VOX SANG. 2022 SEP;1179:1085-1089. WEN LU ET AL. BIOMEDICAL EXCELLENCE FOR SAFER TRANSFUSIONS COLLABORATIVE. HOSPITAL RED BLOOD CELL AND PLATELET SUPPLY AND UTILIZATION FROM MARCH TO DECEMBER OF THE FIRST YEAR OF THE COVID-19 PANDEMIC: THE BEST COLLABORATIVE STUDY. TRANSFUSION. 2022 AUG;628:1559-1570.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Zbigniew Szczepiorkowski President | OfficerTrustee | 20 | $0 |
Michael F Murphy Treasurer | OfficerTrustee | 10 | $0 |
David Mckenna Director Team Leader | Trustee | 5 | $0 |
David Stroncek Director Team Leader | Trustee | 5 | $0 |
Dana Devine Former Director Team Leader | Trustee | 5 | $0 |
Rebecca Caridgan Director Team Leader | Trustee | 5 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $378,750 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $378,750 |
| Total Program Service Revenue | $0 |
| Investment income | $46 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $378,796 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $122,500 |
| Compensation of current officers, directors, key employees. | $30,625 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $500 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $2,663 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $3,400 |
| Office expenses | $3,268 |
| Information technology | $11,975 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $72,219 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $13,001 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $2,472 |
| All other expenses | $0 |
| Total functional expenses | $299,996 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $902,262 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $902,262 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $0 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $902,262 |
| Total liabilities and net assets/fund balances | $902,262 |